Innovent Biologics (09969) climbed more than 6% during early Hong Kong trading, with gains moderating to 5.24% at press time to HK$17.26. Trading volume reached HK$194 million. The biopharmaceutical firm announced that its self-developed novel BCL2 inhibitor mesutoclax (ICP-248), combined with azacitidine for treating myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), has received U.S. Food and Drug Administration (FDA) clearance for clinical studies. Public documentation indicates mesutoclax is a novel oral highly selective BCL2 inhibitor. BCL2 serves as a critical regulatory protein in cellular apoptosis pathways, with its abnormal expression linked to development of various hematological malignancies. By selectively inhibiting BCL2, mesutoclax reactivates programmed cell death mechanisms in tumor cells to exert anti-tumor effects.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。